

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): September 30, 2007

**MEDICAL DISCOVERIES, INC**  
(Exact Name of Registrant as Specified in Charter)

Utah

(State of Incorporation)

000-24569

(Commission File Number)

87-0407858

(I.R.S. Employer Identification No.)

1338 S. Foothill Drive, #266, Salt Lake City, Utah 84108

(Address of Principal Executive Offices)

84108

(Zip Code)

(801) 582-9583

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-

**ITEM 1.01            ENTRY INTO A MATERIAL AGREEMENT**

Amendment to Asset Sale Agreement

As previously reported on a Current Report on Form 8-K filed on September 17, 2007, Medical Discoveries, Inc. (the “Company”), together with its wholly owned subsidiary MDI Oncology, Inc. (“MDI,” and collectively with the Company, the “MDI Entities”), entered into a sale and purchase agreement (the “Asset Sale Agreement”) with Eucodis Pharmaceuticals Forschungs - und Entwicklungs GmbH, an Austrian company (“Eucodis”), pursuant to which Eucodis agreed to acquire certain assets of the Company in consideration for a cash payment and the assumption by Eucodis of certain current indebtedness of the MDI Entities (such transactions, collectively, the “Asset Sale”).

On September 30, 2007, the MDI Entities and Eucodis executed an amendment (the “Amendment”) to the Asset Sale Agreement to, among other things, (i) extend the closing of the Asset Sale through October 31, 2007, and (ii) correct name of the escrow agent set forth therein.

A copy of the Amendment is filed as an exhibit to this Current Report on Form 8-K. The summary of the Amendment set forth above is qualified by reference to such exhibit.

**ITEM 9.01            EXHIBITS**

<u>Exhibit No.</u>	<u>Description</u>
2.1	Amendment to Asset Sale Agreement dated September 30, 2007 among Medical Discoveries, Inc., MDI Oncology, Inc. and Eucodis Pharmaceuticals Forschungs - und Entwicklungs GmbH

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICAL DISCOVERIES, INC.

Date: October 3, 2007

By: /s/ RICHARD PALMER

---

Richard Palmer  
President

---

## EXHIBIT INDEX

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
2.1	Amendment to Asset Sale Agreement dated September 30, 2007 among Medical Discoveries, Inc., MDI Oncology, Inc. and Eucodis Pharmaceuticals Forschungs - und Entwicklungs GmbH

---

## FIRST AMENDMENT TO SALE AND ASSET PURCHASE AGREEMENT

This Amendment (the "Amendment") is made as of this 30<sup>th</sup> day of September 2007 to that certain Sale and Asset Purchase Agreement, dated as of July 6, 2007 (the "Asset Agreement"), by and among Medical Discoveries, Inc., a Utah corporation ("MDI"), MDI Oncology, Inc., a Delaware corporation and wholly-owned subsidiary of MDI ("MDI Oncology"), and Eucodis Pharmaceuticals Forschungs - und Entwicklungs GmbH, an Austrian company ("Eucodis"). Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Asset Agreement.

WHEREAS, the Asset Agreement (including, but not limited to, Sections 3.1 and 4.2 thereof) contemplates that that the transactions thereunder (such transactions, the "Asset Sale") shall close on or before September 30, 2007; and

WHEREAS, the Parties remain committed to closing the Asset Sale, however, desire to extend the period provided for closing the Asset Sale.

NOW, THEREFORE, in consideration of the mutual promises exchanged herein, the Parties agree as follows:

1. Amendment of Asset Agreement.

Section 1.11 of the Asset Agreement is hereby amended and restated in its entirety as to read as follows:

1.11 "Escrow Agent shall mean Emmes Group Consulting LLC."

Section 3.1 (c) of the Asset Agreement is hereby amended and restated in its entirety to read as follows:

(c) "On or before October 31, 2007, EUCODIS shall pay the Excess Portion to the MDI Parties or to another party as the MDI Parties may so direct."

Section 4.2 of the Asset Agreement is hereby amended and restated in its entirety to read as follows:

4.2 "In the event that the Closing does not occur by October 31, 2007, and unless the parties have otherwise agreed in writing, the Escrow Agent shall deliver the Transfer Documents to the MDI Parties or to whomever as the MDI Parties may so direct."

2. No Further Changes. All other provisions of the Asset Agreement shall remain in full force and effect after the execution of this Amendment.

3. Delaware Law Governs. This Amendment shall be governed by and construed under the internal laws of the State of Delaware.

---

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date first written above.

**EUCODIS PHARMACEUTICALS  
FORSCHUNGS-UND ENTWICKLUNGS GmbH**

By: /s/ Wolfgang Schoenfeld

Title: Wolfgang Schoenfeld, M.D.  
Chief Executive Officer

**MEDICAL DISCOVERIES, INC.**

By: /s/ Judy Robinett

Title: Judy Robinett  
Chief Executive Officer

**MDI ONCOLOGY, INC.**

By: /s/ Judy Robinett

Title: Judy Robinett  
Chief Executive Officer

---